Assertio Therapeutics Announces Completion and Final Results of the Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes due 2021 and 5.00% Senior Convertible Notes due 2024GlobeNewsWire • 04/08/20
Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain ProductsGlobeNewsWire • 03/16/20
Assertio Therapeutics Announces Offer to Purchase All of Its Issued and Outstanding 2.50% Senior Convertible Notes Due 2021 and 5.00% Senior Convertible Notes Due 2024GlobeNewsWire • 03/11/20
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 03/09/20
Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 MillionGlobeNewsWire • 02/13/20
Assertio (ASRT) Stock Sinks As Market Gains: What You Should KnowZacks Investment Research • 02/11/20
Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 MillionGlobeNewsWire • 02/06/20
Assertio (ASRT) Dips More Than Broader Markets: What You Should KnowZacks Investment Research • 01/29/20
Is ASSERTIO THERAPEUTICS, INC (ASRT) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 01/22/20
Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior GuidanceGlobeNewsWire • 01/13/20
Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?Zacks Investment Research • 12/23/19
Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 MillionGlobeNewsWire • 12/12/19
Assertio Therapeutics, Inc. (ASRT) CEO Arthur Higgins on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/07/19